The European Commission approved Aegerion Pharmaceuticals' Lojuxta, or lomitapide, as an adjunct therapy to low-fat diet and other lipid-lowering drugs in patients with homozygous familial hypercholesterolemia. The approval was based on data from a late-stage trial.
Aegerion's Lojuxta wins EU approval for hypercholesterolemia
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||